Tesamorelin After a GLP-1: Visceral Fat

Visceral Fat Is Not Belly Fat

Almost every search that leads here uses the phrase "belly fat," and almost every article that answers it treats belly fat as one thing. It is two things, and they behave differently enough that conflating them is the root of most of the confusion in this topic.

Subcutaneous adipose tissue sits between the skin and the abdominal wall. It is the layer you can grab with two fingers. Visceral adipose tissue sits inside the abdominal wall, packed into the omentum and mesentery around the intestines and liver. You cannot pinch it, you cannot see it directly, and someone with a modest waistline can carry a lot of it.

The distinction is not cosmetic. Visceral fat drains through the portal vein straight into the liver, so free fatty acids and inflammatory signals released from those adipocytes arrive at the liver at concentrations the rest of the circulation never sees. Visceral adipocytes are also more lipolytically active and secrete a different adipokine profile than subcutaneous ones. Tchernof and Després reviewed the physiology in detail in Physiological Reviews, and the short version is that the two depots are different tissues doing different things, not the same tissue in two places.

Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359-404. View study

The epidemiology follows the biology. In the Framingham Heart Study, Fox and colleagues imaged both compartments by CT in more than 3,000 participants and found that visceral adipose tissue was more strongly associated with metabolic risk factors than subcutaneous adipose tissue, and that the association held after adjusting for body mass index and waist circumference. In other words, the number on the scale and the tape measure around your waist are proxies, and imperfect ones.

Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116(1):39-48. View study

A 2019 position statement from Neeland and colleagues in The Lancet Diabetes and Endocrinology made the same point at the level of clinical practice: visceral and ectopic fat are the compartments that track with atherosclerosis and cardiometabolic disease, and body mass index alone does not capture them. That is the entire reason a peptide whose primary endpoint was CT-measured visceral fat is worth a separate article.

Neeland IJ, Ross R, Després JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715-725. View study

What the GLP-1 Already Did

A common assumption in this corner of the internet is that GLP-1 weight loss somehow skips visceral fat and takes muscle and subcutaneous fat instead. The imaging data does not support that. A 2023 systematic review and meta-analysis by Liao and colleagues pooled 30 randomized controlled trials covering 1,736 adults and found that GLP-1 receptor agonists significantly reduced visceral adipose tissue, with the effect present in subgroups with and without type 2 diabetes.

Liao C, Liang X, Zhang X, Li Y. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: a systematic review and meta-analysis. PLoS One. 2023;18(8):e0289616. View study

So the concern is not that the GLP-1 left your visceral fat alone. It very likely reduced it. The concern is what happens when the medication stops, and that is a fair concern, because weight regain after discontinuation of a weight-loss medication is well documented and largely expected.

The physiology behind the regain is not specific to GLP-1s at all. Sumithran and colleagues followed people who had lost weight through caloric restriction and measured appetite-regulating hormones at 12 months. Ghrelin remained elevated, leptin and peptide YY remained suppressed, and subjective hunger remained higher than baseline, a full year after the weight loss ended. The body defends a higher weight, and it does so through hunger signals that do not politely reset once you have hit a target.

Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604. View study

The broader question of how to structure the transition off a GLP-1, including the lean mass problem and the taper timing, is covered separately in our coming off Ozempic guide Read nextComing Off Ozempic: A 2026 Peptide Transition GuideWhat happens when you stop a GLP-1, why most patients regain 60-70% of the weight within a year, and the peptide playbook providers use to hold the line on body composition without staying on Ozempic forever.Read article . This article stays narrow: what tesamorelin Explore PeRxTesamorelinMetabolic Optimization PeptideView peptide can and cannot claim in that window.

What Tesamorelin Has Evidence For

Most peptides discussed in this space have rodent studies, a handful of small human trials, and a lot of extrapolation. Tesamorelin is a different situation, and it is worth being specific about why.

Tesamorelin is a full-length 44-amino-acid analog of growth hormone-releasing hormone with a trans-3-hexenoic acid group attached at the N-terminus. That modification blocks the enzyme DPP-IV from cleaving the molecule, which is what native GHRH cannot survive. The result is a peptide that signals the pituitary to release its own growth hormone in the normal pulsatile pattern rather than flooding the system the way injected growth hormone does. The mechanism is covered in more depth in the full tesamorelin guide Read nextTesamorelin 2026: FDA-Approved GHRH for Visceral FatMost peptides have animal studies and early clinical signals. Tesamorelin has two Phase 3 randomized controlled trials, 816 patients, CT-measured visceral fat data, and an FDA approval.Read article .

The clinical program that produced its approval ran in HIV-positive patients with lipodystrophy, a condition in which certain antiretroviral regimens drive pathological visceral fat accumulation. LIPO-010, published by Falutz and colleagues in the New England Journal of Medicine in 2007, randomized 412 patients to tesamorelin 2 mg daily or placebo. Visceral adipose tissue measured by CT fell about 15 percent over 26 weeks in the treated group while it rose in the placebo group. Subcutaneous fat was essentially unchanged. Triglycerides improved.

Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. View study

A second Phase 3 trial, reported by Falutz and colleagues in 2010, enrolled 404 patients and reproduced the result, with a safety extension out to 52 weeks. The extension contained the finding that matters most for anyone thinking about this as a post-GLP-1 tool: patients who were switched from tesamorelin to placebo at week 26 saw their visceral fat drift back toward baseline, while those who continued held their reduction. The effect is maintained by continued use, not banked.

Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-322. View study

Later work extended the picture to the liver. Stanley and colleagues at Massachusetts General Hospital published a randomized trial in JAMA in 2014 showing reductions in both visceral fat and hepatic fat, and a multicenter randomized trial in The Lancet HIV in 2019 focused specifically on non-alcoholic fatty liver disease. Both were conducted in HIV-positive patients.

Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. View study

Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. View study

Reading those five citations together, one pattern is hard to miss. Four of them enrolled HIV-positive patients. That is the population the approval covers, and it is the population where the evidence is strongest. Being precise about that is not a technicality. It is the difference between describing data and describing a hope.

The Non-HIV Trial

There is one randomized trial that most vendor articles about tesamorelin never mention, probably because it is less flattering than the Phase 3 headline numbers. It is also the single most relevant study for anyone who does not have HIV.

Makimura and colleagues randomized 60 abdominally obese adults with reduced growth hormone secretion to tesamorelin 2 mg daily or placebo for 12 months. Visceral adipose tissue was measured by abdominal CT. The treatment effect on visceral fat was a reduction of 35 square centimeters relative to placebo, with a 95 percent confidence interval of 12 to 58 square centimeters and a p value of 0.003. Subcutaneous adipose tissue showed no significant change, p equal to 0.40. Triglycerides, C-reactive protein and carotid intima-media thickness all improved. IGF-1 rose, as expected for a GHRH analog. Fasting glucose, two-hour glucose and glycated hemoglobin did not change significantly.

Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97(12):4769-4779. View study

That result matters for two reasons. It reproduced the compartment selectivity outside the HIV population, which is the strongest argument that the mechanism is not disease-specific. And it did so over a full year rather than 26 weeks.

Where It Might Fit, and Where It Does Not

Here is the honest version of the reasoning, laid out so you can see exactly where it stops being data.

The evidence-backed part: tesamorelin reduces CT-measured visceral adipose tissue in randomized trials, it does so without reducing subcutaneous fat, and the pattern has appeared in two different populations. That is a real, replicated, compartment-specific pharmacological effect, and there is no other peptide in this catalog with that quality of body-composition data.

The inferred part: if the compartment you are worried about after a GLP-1 is the visceral one, and tesamorelin reduces visceral fat in people who were not on a GLP-1, then it may reduce visceral fat in people who were. That is a reasonable inference. It is also, at this point, only an inference. Nobody has run the trial.

Four specific limits are worth holding onto:

The sequence is untested. No published trial has enrolled patients who recently discontinued a GLP-1 receptor agonist and randomized them to tesamorelin. Post-GLP-1 physiology, with its altered appetite signaling and reduced lean mass, is not the physiology of the trial populations.

The effect requires continued use. The 52-week extension data is unambiguous on this. Switch to placebo and visceral fat drifts back. Tesamorelin is not a consolidation therapy that locks in a result and then lets you walk away.

It does nothing about appetite. The mechanism driving post-GLP-1 regain is hunger returning, and a GHRH analog has no effect on that pathway. If the problem you are actually solving is appetite, tesamorelin is not addressing it.

It does not address lean mass by itself. Growth hormone axis peptides are usually discussed alongside resistance training and protein intake for the lean-mass side of the equation, and PeRx offers a tesamorelin and ipamorelin combination Explore PeRxTesamorelin/IpamorelinVisceral Fat & Lean Muscle GH ComboView peptide that pairs the GHRH pathway with a ghrelin-receptor secretagogue. What runs alongside a GLP-1 taper is discussed in more detail in our guide on peptides to take with a GLP-1 Read nextPeptides to Take With a GLP-1: The EvidenceSearch this question and you get a stack. Every result recommends four or five peptides, none of them ranks the options, and none of them tells you which ones have human data behind them. This page sorts the same list into three tiers and says out loud which tier each one lands in.Read article .

It Is Not a Weight-Loss Drug

This deserves its own heading because the search query that brings people here is often some version of "tesamorelin vs semaglutide," and the framing embedded in that question is wrong.

Semaglutide and tirzepatide are agonists at incretin receptors. They suppress appetite, slow gastric emptying and modulate central reward signaling, and the result is a large reduction in total body weight. Tesamorelin is a GHRH analog. It signals the pituitary, raises endogenous growth hormone and IGF-1, and redistributes where fat is stored by preferentially mobilizing the visceral depot. These are not two versions of the same drug class. They are not even solving the same problem.

Look at what the non-HIV trial actually reported: visceral fat down 35 square centimeters relative to placebo, subcutaneous fat unchanged, over 12 months. A person with that result may look somewhat different in the mirror and have better triglycerides, and the scale may barely register it. That is not a failure of the drug. It is what a compartment-selective agent does, and it is why the pivotal trials chose CT imaging as the endpoint rather than body weight.

Protocol and Practical Notes

One regulatory detail that most articles skip. Tesamorelin the molecule is FDA-approved as Egrifta for a narrow indication. A compounded tesamorelin preparation dispensed by a licensed 503A pharmacy against an individual prescription is not that approved product, and it has not itself been through FDA review. The approval heritage is real and it is genuinely unusual for a peptide in this category, but it belongs to the molecule and its studied indication, not to every vial containing it. Anyone selling you tesamorelin as "the FDA-approved peptide" without that sentence attached is blurring something worth keeping clear.

On safety, the picture from the trial program is reassuring but not empty. Injection site reactions were the most common adverse effect. Because tesamorelin raises IGF-1, it is not appropriate with active malignancy, active pituitary pathology, or during pregnancy or breastfeeding. Growth hormone therapy as a class is associated with glucose effects, and while the non-HIV trial found no significant change in fasting glucose, two-hour glucose or glycated hemoglobin, anyone with prediabetes or diabetes should raise that specifically during intake rather than assume it is a non-issue.

Common Questions